Subtle Medical raises $33M and appoints new CEO to scale AI imaging platform

Subtle Medical raises $33M and appoints new CEO to scale AI imaging platform

Menlo Park-based Subtle Medical, a vendor-neutral AI imaging software company, has closed a $33 million Series C led by Morgan Stanley Expansion Capital, with participation from Shinhan Venture Investment, Fusion Fund, EnvisionX, BRV and Samsung Ventures, bringing total funding to $86 million. Co-founder and former CEO Enhao Gong transitions to chief science officer, while medical imaging veteran Ohad Arazi (ex-Zebra Medical Vision, Clarius) takes the helm as CEO. The company's AI layer — deployed on over 1,300 scanners at networks including Mount Sinai, RadNet and Radiology Partners — denoises and sharpens MRI, PET and CT images, enabling up to 80% faster scan times without hardware upgrades.

This Series C is a strong signal for the "context-engineering moat" pattern seen in vertical AI infrastructure: Subtle Medical does not build scanners or replace radiology workflows — it overlays existing installed hardware with a software-only AI layer that boosts throughput and extends asset life. In a hospital environment where imaging capacity is the bottleneck and capital equipment budgets are frozen, a vendor-neutral, FDA-cleared AI overlay that accelerates scans without new MRI purchases addresses a structural economic pain point. The appointment of Arazi, a serial medtech CEO who scaled Zebra Medical Vision through acquisition, suggests the board is positioning for commercial growth and a potential exit path — the acqui-licensing pattern by which imaging OEMs or health IT platforms absorb AI layers rather than building them.

Subtle Medical sits in a crowded but maturing segment of the healthcare AI substrate. Competitors like Aidoc, Arterys and Rad AI have raised similar rounds and pursued adjacent imaging-adjacent workflows. What distinguishes Subtle is its explicit focus on the hardware-extension use case — improving image quality from existing scanners rather than adding a triage or reporting layer. The $33 million round, while modest by foundation-model standards, is significant for a vertical healthcare AI company with 11 FDA clearances and published peer-reviewed evidence; it reflects capital-cycle discipline in a market where enterprise sales cycles and regulatory moats reward patient capital. Gong's retention as chief science officer and continued oversight of China operations also preserves the technical continuity that imaging-network customers require for multi-year deployment commitments.